摘要
目的探讨乳腺癌抗雌激素药物耐药蛋白基因（BCAR1）在子宫内膜样腺癌中的表达及其意义。方法应用免疫组织化学方法检测50例子宫内膜样腺癌和30例子宫内膜单纯性增生组织中BCAR1的表达，并检测雌激素受体（ER）、孕激素受体（PR）在子宫内膜样腺癌的表达。分析BCAR1的表达与子宫内膜样腺癌临床病理特征以及ER、PR的相关性。结果BCAR1在子宫内膜样腺癌组织中的表达[64．0％（32／50）]高于子宫内膜单纯性增生组织中的表达[40．0％（12／30）]，差异有统计学意义（x2=4．364，P=0．037）；在子宫内膜样腺癌中，BCAR1的高表达与患者高龄、肿瘤细胞低分化和ER的阳性表达相关（X2值分别为6．272、5．640、4．217，r值分别为0．354、0．366、0．290；P均〈0．05）。结论BCAR1促进子宫内膜样腺癌的发生，并与肿瘤细胞低分化和ER表达状态呈正相关。
Objective To investigate the expression and significance of BCAR1 protein in endometrial carcinoma. Methods The level of BCAR1 was measured by immunohistochemistry in 50 endometrial carcinoma samples and 30 normal proliferative endometrium samples. Estrogen receptor （ER） and progesterone receptor （PR） expression was investigated in endometrial carcinoma samples. Results The level of BCAR1 was higher in endometrial carcinoma than that in normal proliferative endometrium （64. 0% （32/50） vs. 40.0% （12/30） ; X2 =4. 364,P = 0. 037）. In endometrial cancer, increased BCAR1 expression was significantly correlated with relatively higher age, poor differentiation, positive expression of ER （ X2 = 6. 272, r = 0. 354 ; X2 = 5. 640, r = 0. 366 and X2 = 4. 217, r = 0. 290 ; P 〈 0. 05 ）. Conclusion BCAR1 promote carcinogenesis and positively correlate with poor differentiation and ER status in endometrial carcinoma.
出处
《中国综合临床》
2013年第6期561-564,共4页
Clinical Medicine of China
基金
辽宁省自然科学基金项目（201102297）
